24 May 2013
Keywords: az, hrpc, drug, yields, drop, death, risk
Article | 08 December 2008
AstraZeneca's ZD4054 could improve overall survival in men with metastatic hormone-resistant prostate cancer who were asymptomatic or
mildly symptomatic for ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscriptions are £60 per month, pay as you go.
Find out more details.
8 December 2008
23 May 2013
© 2013 thepharmaletter.com